SCHEDULE: BlackRock Discloses Stake in Zentalis Pharmaceuticals
Schedule 13G Filing
BlackRock, Inc. has reported a beneficial ownership of 5.2% in Zentalis Pharmaceuticals Inc. as of June 30, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Zentalis Pharmaceuticals Inc. common stock.
- As of June 30, 2026, BlackRock beneficially owns 3,710,914 shares, representing 5.2% of the class of securities.
- This ownership includes sole voting power over 3,673,953 shares and sole dispositive power over 3,710,914 shares.
- The filing confirms that no single person has an interest exceeding five percent of the total outstanding common shares.
- BlackRock, Inc. is identified as a holding company (HC) for reporting purposes.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of institutional ownership and does not provide new operational or financial information about Zentalis Pharmaceuticals itself.
Positives
- BlackRock, a significant institutional investor, holds a notable stake in Zentalis Pharmaceuticals, suggesting confidence in the company's long-term prospects.
- The ownership stake of 5.2% indicates a substantial investment by a major financial institution.
Risks
- The filing does not contain specific risk factors related to Zentalis Pharmaceuticals; it is a disclosure of ownership by BlackRock.
- Potential future changes in BlackRock's investment strategy could lead to adjustments in their holdings, impacting Zentalis Pharmaceuticals' stock.
Future Outlook
The filing does not contain forward-looking statements or guidance from Zentalis Pharmaceuticals. It is a disclosure of BlackRock's ownership.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that significant institutional ownership, as disclosed by BlackRock, is a common indicator of investor confidence in the biotechnology and pharmaceutical sectors, where Zentalis Pharmaceuticals operates. Such filings often precede or coincide with key clinical trial updates or strategic developments.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Revocation | The Power of Attorney dated April 30, 2023, was revoked and replaced by a new one dated January 21, 2025. | 01/21/2025 | Ensures updated authorization for individuals to execute regulatory filings on behalf of BlackRock, Inc. |
Stakeholder Impact
- Shareholders of Zentalis Pharmaceuticals: The disclosure confirms a significant institutional investor's stake, which can be viewed positively by the market.
- BlackRock's clients: The investment reflects the management of their assets in accordance with their investment mandates.
Next Steps
- BlackRock will continue to hold or adjust its position in Zentalis Pharmaceuticals' common stock.
- Zentalis Pharmaceuticals may provide further operational or clinical updates in future filings.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney dated April 30, 2023 revoked. |
| 01/21/2025 | Date of execution of the current Power of Attorney by BlackRock, Inc. |
| 06/30/2026 | Date of Event Which Requires Filing of this Statement (Reporting period end date). |
| 07/30/2026 | Date of signature on the Schedule 13G filing. |
Keywords
Zentalis Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.